Literature DB >> 10930677

Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization.

C Schreckenberger1, P Sethupathi, A Kanjanahaluethai, M Müller, J Zhou, L Gissmann, L Qiao.   

Abstract

Human papillomavirus (HPV) plays a crucial role in the development of human anogenital dysplasia. To prevent infection, it is important to induce an HPV-specific mucosal immune response. We investigated whether DNA vaccination would induce an intravaginal mucosal antibody response against HPV 6bL1. New Zealand White rabbits were immunized with an HPV 6bL1 DNA vaccine by one of the three routes: muscular, vaginal, or rectal. We found that vaginal immunization of rabbits with HPV 6bL1 DNA induced 6bL1 virus-like particle-specific lgA antibodies in vaginal secretions. They were detectable until at least 14 weeks after the first immunization. The antibodies also showed neutralizing activity in a hemagglutination inhibition assay. No mucosal immune response was detected in vaginal secretions of rabbits immunized intramuscularly or intrarectally. Our data suggest that vaginal immunization with HPV 6bL1 DNA induces long-lasting IgA responses with neutralizing activity in vaginal secretions of rabbits.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930677     DOI: 10.1016/s0264-410x(00)00173-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

5.  Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.

Authors:  Dirk Kuck; Tobias Lau; Barbara Leuchs; Andrea Kern; Martin Müller; Lutz Gissmann; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

6.  Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.

Authors:  C Leder; J A Kleinschmidt; C Wiethe; M Müller
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 7.  Vaginal delivery of vaccines.

Authors:  Hannah M VanBenschoten; Kim A Woodrow
Journal:  Adv Drug Deliv Rev       Date:  2021-09-01       Impact factor: 15.470

8.  Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses.

Authors:  M P Cranage; C A Fraser; Z Stevens; J Huting; M Chang; S A Jeffs; M S Seaman; A Cope; T Cole; R J Shattock
Journal:  Mucosal Immunol       Date:  2009-09-09       Impact factor: 7.313

Review 9.  Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?

Authors:  Mattia Tiboni; Luca Casettari; Lisbeth Illum
Journal:  Int J Pharm       Date:  2021-05-06       Impact factor: 6.510

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.